Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atafenovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Novagenix Bioanalytical R&D Center | Farmagen Ar-Ge
Deal Size : Inapplicable
Deal Type : Inapplicable
The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 20, 2020
Lead Product(s) : Atafenovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Novagenix Bioanalytical R&D Center | Farmagen Ar-Ge
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Novagenix Bioanalytical R&D Center | Farmagen Ar-Ge
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Novagenix Bioanalytical R&D Center | Farmagen Ar-Ge
Deal Size : Inapplicable
Deal Type : Inapplicable